Establishment of a transgenic mouse model with coagulation factor V mutation, but with no obvious changes of bone tissue

doi:10.3969/j.issn.2095-4344.2016.46.003

Abstract

Abstract:

BACKGROUND: Blood coagulation factor V gene mutation in non-traumatic femoral head necrosis has been shown to have an higher incidence than that in healthy and secondary non-traumatic femoral head necrosis, and the incidence of thrombosis is positively related. Inactivated blood coagulation factor V can accelerate the activation of prothrombin and the generation of thrombin. Mutations at arg-306, arg-506 and arg-679 will result in the blood clots and hypercoagulable state. Here, this study is designed to investigate the influence of R506Q/R679Q on osteonecrosis.
OBJECTIVE: To establish the mouse model of mutations of Gln506Arg and Gln679Arg in coagulation Factor V (Factor VR506Q/R679Q).
METHODS: Factor VR506Q/R679Q point mutation target vector was constructed by molecular cloning technology, the linearization vector was transfected into embryonic stem cells, and then G418-resistant cells were screened and used for microinjection. The target blastocysts were transplanted to the fallopian tube of estrus mice to obtain the Chimera mice carrying bilateral LoxP gene, followed by mated with CMV-cre transgenic mice, and then the mice with Factor VR506Q/R679Q point mutations were obtained. After genotype identification by PCR, hematoxylin-eosin staining results and percentage of empty lacunae were compared between the mutant and wild-type mice, and rat bone tissue and bone mass were analyzed.
RESULTS AND CONCLUSION: There were no obvious abnormalities in the embryonic and postnatal development, percentage of empty lacunae and bone mass of Factor VR506Q/R679Q point mutation mice when compared with the wild-type mice. These results suggest that the mouse model with Factor VR506Q/R679Q point mutation is established successfully, but there is no significant change in the bone tissue. The following research should focus on the effect of external stimulus on the incidence of osteonecrosis in a mutant mouse.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Models, Animal, Genes, Blood Coagulation Factors, Tissue Engineering

CLC Number:

R318

Wang Yu-ying, Zhang Yan, Qi Jin-wei, Yin Zhao-guang. Establishment of a transgenic mouse model with coagulation factor V mutation, but with no obvious changes of bone tissue[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(46): 6861-6867.

Figures/Tables 2

References

[1] Arlet J. Nontraumatic avascular necrosis of the femoral head. Past, Present, and Future. Clin Orthop Relat Res. 1992;277:12-21.
[2] Mont MA, Hungerford DS. Current concepts review. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am. 1995;77:459-474.
[3] Fisher DE. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin Orthop Relat Res. 1978;130: 68-80.
[4] Wang Y, Li Y, Mao K, et al. Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clin Orthop Relat Res. 2003;410:213-224.
[5] Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol. 2003; 25:13-24.
[6] Wang TY, Avlonitis EG, Relkin R. Systemic necrotizing vasculitis causing bone necrosis. Am J Med. 1988;84: 1085-1086.
[7] Massin P, Duparc J. Total hip replacement in irradiated hips: a retrospective study of 71 cases. J Bone Joint Surg Br. 1995;77:847-852.
[8] Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
[9] Lehner CE, Wilson MA, Dueland RT, et al. Sheep model of dysbaric osteonecrosis in divers and cais-son workers. In: Urbaniak JR, Jones JP Jr, eds. Osteonecrosis - Etiology, Diagnosis, and Treatment. Rosemont, IL: American Academy of Orthopaedic Surgeons, 1997:145-152.
[10] Yang L, Boyd K, Kaste SC, et al. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res.2009;27(2):169-175.
[11] Takaoka K, Yoshioka T, Hosoya T, et al. The repair process inexperimentally inducedavascular necrosis of the femoral head in dogs. Arch Orthop Trauma Surg, 1981;99(2): 109-115.
[12] Li Y, Han R, Geng C, et al. A new osteonecrosis animal model of the femoral head induced by microwave heating and repaired with tissue engineered bone. Int Orthop. 2009;33(2):573-580.
[13] Chang G. Non-traumatic osteonecrosis of the femoral head - from clinical to bench. Med J. 2010;33(4): 351-360.
[14] Jones JP Jr. Risk factors potentially activating intravascu-lar coagulation and causing nontraumatic osteonecrosis. In: Urbaniak JR, Jones JP Jr, eds. Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL: American Academy of Orthopaedic Surgeons, 1997:89-97.
[15] Glueck CJ, Freiberg RA, Wang P. Detecting thrombophilia, hypo-fibrinolysis, and reduced nitric oxide production in osteonecrosis. Semin Artrhoplasty. 2007;18:184-191.
[16] Vosmaer A, Pereira RR, Koenderman JS, et al. Coagulation abnormalities in Legg-Calve-Perthes disease. J Bone Joint Surg Am. 2010;92(1):121-128.
[17] Glueck CJ, McMahon RE, Bouquot JE, et al. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med. 1997;130(5): 540-543.
[18] Björkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004;(425):168-172.
[19] Glueck CJ, Freiberg RA, Boriel G, et al. The Role of the Factor V Leiden Mutation in Osteonecrosis of the Hip. Clin Appl Thromb Hemost. 2013;19(5):499-503.
[20] Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost.2001;86: 51-56.
[21] Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269(50): 31869-31880.
[22] Gale AJ, Yegneswaran S, Xu X, et al.Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein Ccleavage site. J Biol Chem. 2007;282(30):21848-21855.
[23] van der Neut Kolfschoten M, Dirven RJ, Vos HL, et al. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679. J Biol Chem. 2004;279(8):6567-6575.
[24] Reitsma PH, van de Stolpe A. From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A. Ned Tijdschr Geneeskd. 2001; 145(38):1843-1845.
[25] Glueck CJ, Glueck HI, Greenfield D, et al. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res. 1994;35(4 Pt 1):383-388.
[26] Glueck CJ, Brandt G, Gruppo R,et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop Relat Res. 1997;(338):139-152.
[27] Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
[28] Greengard JS, Sun X, Xu X,et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343(8909):1361-1362.
[29] Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85(6):1504-1508.
[30] Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343 (8912):1535-1536.
[31] Ridker PM, Hennekens CH, Lindpaintner K,et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912-917.
[32] Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133-1134.
[33] Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood. 1998; 91(4): 1140-1144.
[34] Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91(4):1135-1139.
[35] Franco RF, Maffei FH, Lourenço D, et al. Factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in venous thrombotic disease. Br J Haematol. 1998;103(3):888-890.
[36] Barhoover MA, Kalafatis M. Cleavage atboth Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C. Blood Coagul Fibrinolysis. 2011;22(4):317-324.
[37] Norstrøm E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100(2):524-530.
[38] Kita T, Banno F, Yanamoto H, et al. Large infarct and high mortality by cerebral ischemia in mice carrying the factor V Leiden mutation. J Thromb Haemost. 2012; 10(7):1453-1455.
[39] Shanmugam VK, McNish S, Duncan J, et al. Late failure of a split-thickness skin graft in the setting of homozygous factor V Leiden mutation: a case report and correlative animal model from the Wound Etiology and Healing (WE-HEAL) study. Int Wound J. 2015; 12(5):537-544.
[40] Kerschen E, Hernandez I, Zogg M, et al. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. J Thromb Haemost. 2015;13(6): 1073-1080.
[41] Liang HP, Kerschen EJ, Basu S, et al. Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood. 2015;126(21):2415- 2423.